Severity of Pruritus Related to Quality of Life
The severity of pruritus was correlated with quality of life among individuals with atopic dermatitis (AD), according to a recent poster study. Findings from the study were presented at the 2018 American Academy of Dermatology Annual Meeting.
Using pooled data from 2 large clinical trials, Sonja Ständer, MD, and colleagues examined the relationship between pruritus and quality of life (QoL). In the trials, 1016 participants were randomized to the crisaborole (Eucrisa) group and 506 were randomized to the vehicle group. Participants applied either crisaborole or vehicle 2 times per day for 29 days. Itch severity was assessed using the Severity of Pruritus Scale (SPS). Quality of life was assessed using the Dermatology Life Quality Index (DLQI) among participants age 16 years and older and Children’s Dermatology Life Quality Index (CDLQI) among participants aged 2 to 15 years.
AD Treatment Rapidly Reduces Pruritus
Scalp Pruritus: Itching for Treatment Part 2
Dr Ständer and her team observed a significant positive association between SPS scores and QoL. In analysis that linked the severity of pruritus with DLQI and CDLQI, they found that SPS scores were association with worsening QoL. In addition, their analysis showed a linear relationship between SPS scores and DLQI and CDLQI scores.
“Linking of SPS score to corresponding DLQI and CDLQI severity bands allows clinicians to easily gauge the impact of severity of pruritus on the QoL of their patients,” the researchers concluded. “The near-identical relationship between SPS score and patient QoL for the DLQI and CDLQI shows the generalizability of the relationship between pruritus and QoL across different ages.”
“Based on results of the 2 phase 3 studies, the observed relationship between SPS score and DLQI or CDLQI scores provide clear evidence of the significant link between pruritus and patient QoL in mild to moderate AD.”
Ständer S, Yosipovitch G, Bushmakin AG, et al. Relationship between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. Presented at: American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA.